SPStine Elleberg Petersen

Stine Elleberg Petersen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stine Elleberg Petersen has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Spatial rectal dose/volume metrics predict patient-reported gastro-intestinal symptoms after radiotherapy for prostate cancer

    by Oscar Casares-Magaz, Ludvig Paul Muren, Vitali Moiseenko, Stine E. Petersen, Niclas Johan Pettersson, Morten Høyer, Joseph O. Deasy, Maria Thor

    Background: Gastro-intestinal (GI) toxicity after radiotherapy (RT) for prostate cancer reduces patient’s quality of life. In this study, we explored associations between spatial rectal dose/volume metrics and patient-reported GI symptoms after RT for localized prostate cancer, and compared these with those of dose–surface/volume histogram (DSH/DVH) metrics. Material and methods: Dose distributions and six GI symptoms (defecation urgency/emptying difficulties/fecal leakage, ≥Grade 2, median follow-up: 3.6 y) were extracted for 200 patients treated with image-guided RT in 2005–2007. Three hundred and nine metrics assessed from 2D rectal dose maps or DSHs/DVHs were subject to 50-times iterated five-fold cross-validated univariate and multivariate logistic regression analysis (UVA, MVA). Performance of the most frequently selected MVA models was evaluated by the area under the receiving–operating characteristics curve (AUC). Results: The AUC increased for dose-map compared to DSH/DVH-based models (mean SD: 0.64 ± 0.03 vs. 0.61 ± 0.01), and significant relations were found for six versus four symptoms. Defecation urgency and faecal leakage were explained by high doses at the central/upper and central areas, respectively; while emptying difficulties were explained by longitudinal extensions of intermediate doses. Conclusions: Predictability of patient-reported GI toxicity increased using spatial metrics compared to DSH/DVH metrics. Novel associations were particularly identified for emptying difficulties using both approaches in which intermediate doses were emphasized.


  • Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer

    by Maria Ervandian, Morten Høyer, Stine Elleberg Petersen, Lisa Sengeløv, Steinbjørn Hansen, Mette Moe Kempel, Peter Meidahl Petersen, Michael Borre

    Objective: There is a paucity of knowledge of long-term urinary morbidity in patients treated for prostate cancer (PCa) with radical prostatectomy (RP) and salvage radiotherapy (SRT). Improved long-term survival calls for heightened awareness of late effects from radiotherapy after RP. The purpose of this study was to assess late urinary morbidity and its potential impact on quality of life (QoL) in patients treated with RP plus SRT compared with patients treated with RP alone. Materials and methods: Long-term morbidity and QoL were evaluated using a cross-sectional design with validated questionnaires in urinary morbidity [Danish Prostatic Symptom Score (DAN-PSS)] and QoL [European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)]. Included were a total of 227 patients treated with SRT and 192 treated with RP in the periods 2006–2010 and 2005–2007, respectively. Results: Weak stream, straining, frequency and nocturia were significantly more prevalent in patients treated with RP + SRT than in patients treated with RP alone. Patients treated with RP + SRT generally suffered from more severe urinary symptoms. The QoL scores of the two treatment groups were not statistically significantly different, but a high level of urinary morbidity was significantly related to decreased QoL (p = 0.000). Conclusions: Patients treated with SRT have a higher rate of urinary morbidity than do patients treated with RP alone. Severe urinary morbidity was significantly related to decreased QoL, but did not differ between the two treatment groups.


  • Open Access

    Urinary bladder dose–response relationships for patient-reported genitourinary morbidity domains following prostate cancer radiotherapy

    by Maria Thor, Caroline Olsson, Jung Hun Oh, Stine Elleberg Petersen, David Alsadius, Lise Bentzen, Niclas Pettersson, Ludvig Paul Muren, Morten Høyer, Gunnar Steineck, et al.


  • Development and validation of a scoring system for late anorectal side-effects in patients treated with radiotherapy for prostate cancer

    by Stine Elleberg Petersen, Lise Bentzen, Katrine J. Emmertsen, Søren Laurberg, Lilli Lundby, Morten Høyer